The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

Massimo Cristofanilli; Jean-Yves Pierga; James Reuben; Alfred Rademaker; Andrew A Davis; Dieter J Peeters; Tanja Fehm; Franco Nolé; Rafael Gisbert-Criado; Dimitrios Mavroudis; Salvatore Grisanti; Mario Giuliano; Jose A Garcia-Saenz; Justin Stebbing; Carlos Caldas; Paola Gazzaniga; Luis Manso; Rita Zamarchi; Angela Fernandez de Lascoiti; Leticia De Mattos-Arruda; Michail Ignatiadis; Luc Cabel; Steven J van Laere; Franziska Meier-Stiegen; Maria-Teresa Sandri; Jose Vidal-Martinez; Eleni Politaki; Francesca Consoli; Daniele Generali; Maria Rosa Cappelletti; Eduardo Diaz-Rubio; Jonathan Krell; Sarah-Jane Dawson; Cristina Raimondi; Annemie Rutten; Wolfgang Janni; Elisabetta Munzone; Vicente Carañana; Sofia Agelaki; Camillo Almici; Luc Dirix; Erich-Franz Solomayer; Laura Zorzino; Lauren Darrigues; Jorge S Reis-Filho; Lorenzo Gerratana; Stefan Michiels; François-Clément Bidard; Klaus Pantel

doi:10.1016/j.critrevonc.2018.12.004

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

Massimo Cristofanilli, Jean-Yves Pierga, James Reuben, Alfred Rademaker, Andrew A Davis, Dieter J Peeters, Tanja Fehm, Franco Nolé, Rafael Gisbert-Criado, Dimitrios Mavroudis, Salvatore Grisanti, Mario Giuliano, Jose A Garcia-Saenz, Justin Stebbing, Carlos Caldas, Paola Gazzaniga, Luis Manso, Rita Zamarchi, Angela Fernandez de Lascoiti, Leticia De Mattos-ArrudaMichail Ignatiadis, Luc Cabel, Steven J van Laere, Franziska Meier-Stiegen, Maria-Teresa Sandri, Jose Vidal-Martinez, Eleni Politaki, Francesca Consoli, Daniele Generali, Maria Rosa Cappelletti, Eduardo Diaz-Rubio, Jonathan Krell, Sarah-Jane Dawson, Cristina Raimondi, Annemie Rutten, Wolfgang Janni, Elisabetta Munzone, Vicente Carañana, Sofia Agelaki, Camillo Almici, Luc Dirix, Erich-Franz Solomayer, Laura Zorzino, Lauren Darrigues, Jorge S Reis-Filho, Lorenzo Gerratana, Stefan Michiels, François-Clément Bidard, Klaus Pantel

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease.METHODS: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IVaggressive, those with <5 CTCs as Stage IVindolent. Survival was analyzed using Kaplan-Meier curves and the log rank test.RESULTS: For all patients, Stage IVindolent patients had longer median overall survival than those with Stage IVaggressive (36.3 months vs. 16.0 months, P

Original language	English
Pages (from-to)	39-45
Number of pages	7
Journal	Critical Reviews in Oncology/Hematology
Volume	134
DOIs	https://doi.org/10.1016/j.critrevonc.2018.12.004
Publication status	Published - Feb 2019

Keywords

Biomarkers, Tumor/analysis
Breast Neoplasms/pathology
Consensus
Expert Testimony
Female
Humans
International Agencies
Neoplasm Staging/standards
Neoplastic Cells, Circulating/pathology
Patient Selection

Access to Document

10.1016/j.critrevonc.2018.12.004

Cite this

Cristofanilli, M., Pierga, J-Y., Reuben, J., Rademaker, A., Davis, A. A., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Giuliano, M., Garcia-Saenz, J. A., Stebbing, J., Caldas, C., Gazzaniga, P., Manso, L., Zamarchi, R., de Lascoiti, A. F., ... Pantel, K. (2019). The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology, 134, 39-45. https://doi.org/10.1016/j.critrevonc.2018.12.004

Cristofanilli, M, Pierga, J-Y, Reuben, J, Rademaker, A, Davis, AA, Peeters, DJ, Fehm, T, Nolé, F, Gisbert-Criado, R, Mavroudis, D, Grisanti, S, Giuliano, M, Garcia-Saenz, JA, Stebbing, J, Caldas, C, Gazzaniga, P, Manso, L, Zamarchi, R, de Lascoiti, AF, De Mattos-Arruda, L, Ignatiadis, M, Cabel, L, van Laere, SJ, Meier-Stiegen, F, Sandri, M-T, Vidal-Martinez, J, Politaki, E, Consoli, F, Generali, D, Cappelletti, MR, Diaz-Rubio, E, Krell, J, Dawson, S-J, Raimondi, C, Rutten, A, Janni, W, Munzone, E, Carañana, V, Agelaki, S, Almici, C, Dirix, L, Solomayer, E-F, Zorzino, L, Darrigues, L, Reis-Filho, JS, Gerratana, L, Michiels, S, Bidard, F-C & Pantel, K 2019, 'The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper', Critical Reviews in Oncology/Hematology, vol. 134, pp. 39-45. https://doi.org/10.1016/j.critrevonc.2018.12.004

@article{35e14d515f8d462b8daa0d4f1062fde7,

title = "The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper",

abstract = "BACKGROUND: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease.METHODS: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IVaggressive, those with <5 CTCs as Stage IVindolent. Survival was analyzed using Kaplan-Meier curves and the log rank test.RESULTS: For all patients, Stage IVindolent patients had longer median overall survival than those with Stage IVaggressive (36.3 months vs. 16.0 months, P ",

keywords = "Biomarkers, Tumor/analysis, Breast Neoplasms/pathology, Consensus, Expert Testimony, Female, Humans, International Agencies, Neoplasm Staging/standards, Neoplastic Cells, Circulating/pathology, Patient Selection",

author = "Massimo Cristofanilli and Jean-Yves Pierga and James Reuben and Alfred Rademaker and Davis, {Andrew A} and Peeters, {Dieter J} and Tanja Fehm and Franco Nol{\'e} and Rafael Gisbert-Criado and Dimitrios Mavroudis and Salvatore Grisanti and Mario Giuliano and Garcia-Saenz, {Jose A} and Justin Stebbing and Carlos Caldas and Paola Gazzaniga and Luis Manso and Rita Zamarchi and {de Lascoiti}, {Angela Fernandez} and {De Mattos-Arruda}, Leticia and Michail Ignatiadis and Luc Cabel and {van Laere}, {Steven J} and Franziska Meier-Stiegen and Maria-Teresa Sandri and Jose Vidal-Martinez and Eleni Politaki and Francesca Consoli and Daniele Generali and Cappelletti, {Maria Rosa} and Eduardo Diaz-Rubio and Jonathan Krell and Sarah-Jane Dawson and Cristina Raimondi and Annemie Rutten and Wolfgang Janni and Elisabetta Munzone and Vicente Cara{\~n}ana and Sofia Agelaki and Camillo Almici and Luc Dirix and Erich-Franz Solomayer and Laura Zorzino and Lauren Darrigues and Reis-Filho, {Jorge S} and Lorenzo Gerratana and Stefan Michiels and Fran{\c c}ois-Cl{\'e}ment Bidard and Klaus Pantel",

note = "Copyright {\textcopyright} 2018. Published by Elsevier B.V.",

year = "2019",

month = feb,

doi = "10.1016/j.critrevonc.2018.12.004",

language = "English",

volume = "134",

pages = "39--45",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC)

T2 - International expert consensus paper

AU - Cristofanilli, Massimo

AU - Pierga, Jean-Yves

AU - Reuben, James

AU - Rademaker, Alfred

AU - Davis, Andrew A

AU - Peeters, Dieter J

AU - Fehm, Tanja

AU - Nolé, Franco

AU - Gisbert-Criado, Rafael

AU - Mavroudis, Dimitrios

AU - Grisanti, Salvatore

AU - Giuliano, Mario

AU - Garcia-Saenz, Jose A

AU - Stebbing, Justin

AU - Caldas, Carlos

AU - Gazzaniga, Paola

AU - Manso, Luis

AU - Zamarchi, Rita

AU - de Lascoiti, Angela Fernandez

AU - De Mattos-Arruda, Leticia

AU - Ignatiadis, Michail

AU - Cabel, Luc

AU - van Laere, Steven J

AU - Meier-Stiegen, Franziska

AU - Sandri, Maria-Teresa

AU - Vidal-Martinez, Jose

AU - Politaki, Eleni

AU - Consoli, Francesca

AU - Generali, Daniele

AU - Cappelletti, Maria Rosa

AU - Diaz-Rubio, Eduardo

AU - Krell, Jonathan

AU - Dawson, Sarah-Jane

AU - Raimondi, Cristina

AU - Rutten, Annemie

AU - Janni, Wolfgang

AU - Munzone, Elisabetta

AU - Carañana, Vicente

AU - Agelaki, Sofia

AU - Almici, Camillo

AU - Dirix, Luc

AU - Solomayer, Erich-Franz

AU - Zorzino, Laura

AU - Darrigues, Lauren

AU - Reis-Filho, Jorge S

AU - Gerratana, Lorenzo

AU - Michiels, Stefan

AU - Bidard, François-Clément

AU - Pantel, Klaus

PY - 2019/2

Y1 - 2019/2

N2 - BACKGROUND: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease.METHODS: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IVaggressive, those with <5 CTCs as Stage IVindolent. Survival was analyzed using Kaplan-Meier curves and the log rank test.RESULTS: For all patients, Stage IVindolent patients had longer median overall survival than those with Stage IVaggressive (36.3 months vs. 16.0 months, P

AB - BACKGROUND: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease.METHODS: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IVaggressive, those with <5 CTCs as Stage IVindolent. Survival was analyzed using Kaplan-Meier curves and the log rank test.RESULTS: For all patients, Stage IVindolent patients had longer median overall survival than those with Stage IVaggressive (36.3 months vs. 16.0 months, P

KW - Biomarkers, Tumor/analysis

KW - Breast Neoplasms/pathology

KW - Consensus

KW - Expert Testimony

KW - Female

KW - Humans

KW - International Agencies

KW - Neoplasm Staging/standards

KW - Neoplastic Cells, Circulating/pathology

KW - Patient Selection

U2 - 10.1016/j.critrevonc.2018.12.004

DO - 10.1016/j.critrevonc.2018.12.004

M3 - Article

SN - 1040-8428

VL - 134

SP - 39

EP - 45

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

ER -

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

Abstract

Keywords

Access to Document

Fingerprint

Cite this